Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$155.41 USD

155.41
3,624,673

-0.06 (-0.04%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

    Swarup Gupta headshot

    Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao

    by Swarup Gupta

    The Dow notched up a record streak of gains over a holiday shortened week.

      Johnson & Johnson (JNJ) Up 6% Since Earnings Report: Can It Continue?

      by Zacks Equity Research

      Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Geron (GERN) Q4 Earnings: What's in Store for the Stock?

        by Zacks Equity Research

        Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

          Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

          by Zacks Equity Research

          Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

            Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

            by Zacks Equity Research

            Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.

              Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

              by Zacks Equity Research

              The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

                Arpita Dutt headshot

                4 Drug Stocks that are Broker Favorites

                by Arpita Dutt

                Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.

                  Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

                  by Zacks Equity Research

                  Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.

                    Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down

                    by Zacks Equity Research

                    Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines

                        Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN

                        by Zacks Equity Research

                        How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?

                          Mark Vickery headshot

                          Top Research Reports for February 1, 2017

                          by Mark Vickery

                          Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), PayPal (PYPL) and Thermo Fisher (TMO).

                            Madeleine Johnson headshot

                            Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

                            by Madeleine Johnson

                            Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                              Ryan McQueeney headshot

                              Biotech Stocks Gain on Latest Trump Drug Price Statements

                              by Ryan McQueeney

                              President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

                                Kinjel Shah headshot

                                Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

                                by Kinjel Shah

                                Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

                                  Swarup Gupta headshot

                                  Dow 30 Stock Roundup: Boeing, Caterpillar, Johnson & Johnson, DuPont Beat on Earnings

                                  by Swarup Gupta

                                  The Dow gained over the week following continuing optimism over Trump's first actions as President and encouraging earnings results.

                                    Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

                                    by Zacks Equity Research

                                    We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

                                      J&J to Acquire Actelion for $30B: Is It a Strategic Fit?

                                      by Zacks Equity Research

                                      Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Actelion (ALIOF) for $280 per share, as of Jan 25, 2017, in an all-cash transaction.

                                        Madeleine Johnson headshot

                                        For $30 Billion, Johnson & Johnson is Acquiring Swiss Biotech Actelion

                                        by Madeleine Johnson

                                        On Thursday, healthcare giant Johnson & Johnson (JNJ) announced it will acquire Swiss biotechnology company Actelion for $30 billion in order to boost its roster of rare disease treatments.

                                          Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

                                          by Zacks Equity Research

                                          Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

                                            The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                                              What Lies in Store for Pfizer (PFE) this Earnings Season?

                                              by Zacks Equity Research

                                              Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.

                                                Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                                                by Zacks Equity Research

                                                How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                                                  Eric Dutram headshot

                                                  Is Customer Satisfaction the Hidden Key to Stock Outperformance?

                                                  by Eric Dutram

                                                  In this edition of the Dutram Report, we take a closer look at the idea of customer satisfaction. Do companies that serve their customers better end up being more impressive investments? In order to get to the bottom of this, I spoke with Kevin Quigg, Chief Strategist of ACSI Funds for some answers and insights.